POS-546 EFFICACY AND SAFETY OF IPTACOPAN IN IgA NEPHROPATHY: RESULTS OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY AT 6 MONTHS
Jonathan Barratt, Brad H. Rovin, Hengguo Zhang, Naoki Kashihara, Bart Maes, Dana V. Rizk, Hernán Trimarchi, Ben Sprangers, Matthias Meier, Dmitrij Kollins, W. Wang, Annabel R. Magirr, Vlado Perkovic
Abstract
No approved targeted therapies currently exist for IgA nephropathy (IgAN). Targeting the alternative complement pathway (AP) is an attractive therapeutic strategy given its role in the pathogenesis of IgAN. Iptacopan (LNP023) is a first-in-class, oral, potent and highly selective inhibitor of factor B of AP.
Topics & Concepts
MedicineNephropathyPlaceboPathogenesisAlternative complement pathwayComplement (music)Double blindInternal medicineComplement systemImmunologyAntibodyPathologyEndocrinologyAlternative medicinePhenotypeChemistryGeneComplementationBiochemistryDiabetes mellitusRenal Diseases and GlomerulopathiesComplement system in diseasesPregnancy and Medication Impact